Marwa Al-Badri

Dr. Marwa Al-Badri

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MAMarwa Al-Badri
Marwa Al-Badri
OHOsama Hamdy
Osama Hamdy
Diabetes is a chronic disease that affects nearly 463 million people globally and involves multiple co-morbid conditions that require effective treatment and continuous management. These include lifestyle and behavioral modifications, compliance to diabetes medications and close patient monitoring, all of which can be efficiently conducted via telehealth. Integrating digital technology of telehealth and mobile health into diabetes care may improve diabetes management and increase its efficiency. In this review, we examine recent advances in healthcare technology of diabetes. Moreover, we present an example of a comprehensive virtual diabetes clinic, the “Joslin HOME,” as an innovative digital ecosystem for future application in diabetes care. This model utilizes digital health technology and comprises frequent short visits with easy two-way scheduling, focused documentation and simple billing methods. In this new model, a multidisciplinary team is connected with their patients using telehealth and mobile health to overcome the barriers of distance and location. It may possibly extend quality diabetes care to remote, underserved or rural areas.

1 January 2022 in Therapeutic Advances in Endocrinology and Metabolism
Verified
Journal Article
Open access
MAMarwa Al-Badri
Marwa Al-Badri
CKCara L. Kilroy
Cara L. Kilroy
JSJacqueline Ifat Shahar
Jacqueline Ifat Shahar
STShaheen Tomah
Shaheen Tomah
HGHannah Gardner
Hannah Gardner
OHOsama Hamdy
Osama Hamdy
Background: Intensive lifestyle intervention (ILI) is essential for diabetes management. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary weight management program that has been implemented in real-world clinical practice since 2005 and has shown long-term maintenance of weight reduction for 5 and 10 years. During the COVID-19 pandemic, the program went virtual using telemedicine and mobile health applications. Aims: This retrospective pilot study aims to evaluate the effectiveness of a virtual model of an already established and successful in-person program for diabetes and weight management since 2005. Methods: We evaluated 38 patients with diabetes and obesity enrolled in the Why WAIT program between February 2019 and December 2020. Sixteen participants were enrolled in virtual program (VP) and were compared with 22 participants who completed the latest two physical programs (PPs) before COVID-19. We evaluated changes in body weight, A1C, blood pressure (BP), and lipid profile after 12 weeks of ILI. Results: Body weight decreased by −7.4 ± 3.6 kg from baseline in VP compared with −6.8 ± 3.5 kg in PP ( p = 0.6 between groups). A1C decreased by −1.03% ± 1.1% from baseline in VP, and by −1.0% ± 1.2% in PP ( p = 0.9 between groups). BP, lipid profile, and all other parameters improved in both groups with no significant difference between them. Conclusion: Virtual multidisciplinary ILI is as effective as the in-person intervention program in improving body weight, A1C, BP, and lipid profile, and in reducing the number of anti-hyperglycemic medications. Results from our study suggest that scaling the Why WAIT program in a virtual format to a larger population of patients with diabetes and obesity is feasible and is potentially as successful as the in-person program.

22 May 2023 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
STShaheen Tomah
Shaheen Tomah
HZHongxia Zhang
Hongxia Zhang
MAMarwa Al-Badri
Marwa Al-Badri
TSTareq Salah
Tareq Salah
SDShilton E. Dhaver
Shilton E. Dhaver
OHOsama Hamdy
Osama Hamdy
Introduction Intensive lifestyle intervention (ILI) has significantly reduced incidence of diabetes and improved many cardiovascular disease risk factors. We evaluated long-term effects of ILI on cardiometabolic risk factors, and microvascular and macrovascular complications among patients with diabetes in real-world clinical practice. Research design and methods We evaluated 129 patients with diabetes and obesity enrolled in a 12-week translational model of ILI. At 1 year, we divided participants into group A, who maintained <7% weight loss (n=61, 47.7%), and group B, who maintained ≥7% weight loss (n=67, 52.3%). We continued to follow them for 10 years. Results The total cohort lost an average of 10.8±4.6 kg (−9.7%) at 12 weeks and maintained an average weight loss of 7.7±10 kg (−6.9%) at 10 years. Group A maintained 4.3±9.5 kg (−4.3%) and group B maintained 10.8±9.3 kg (−9.3%) of weight loss at 10 years (p<0.001 between groups). In group A, A1c decreased from 7.5±1.3% to 6.7±0.9% at 12 weeks but rebounded to 7.7±1.4% at 1 year and 8.0±1.9% at 10 years. In group B, A1c decreased from 7.4±1.2% to 6.4±0.9% at 12 weeks then increased to 6.8±1.2% at 1 year and 7.3±1.5% at 10 years (p<0.05 between groups). Maintenance of ≥7% weight loss at 1 year was associated with a 68% lower risk of developing nephropathy for up to 10 years compared with maintenance of <7% weight loss (adjusted HR for group B: 0.32, 95% CI 0.11, 0.9, p=0.007). Conclusions Weight reduction in patients with diabetes can be maintained for up to 10 years in real-world clinical practice. Sustained weight loss is associated with significantly lower A1c at 10 years and improvement in lipid profile. Maintenance of ≥7% weight loss at 1 year is associated with decreased incidence of diabetic nephropathy at 10 years.

24 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
SDShilton E. Dhaver
Shilton E. Dhaver
MAMarwa Al-Badri
Marwa Al-Badri
JMJoanna Mitri
Joanna Mitri
AAAbd Almasih Barbar Askar
Abd Almasih Barbar Askar
AMAdham Mottalib
Adham Mottalib
OHOsama Hamdy
Osama Hamdy
Background: Almond milk is often seen as a healthier alternative to cow milk. However, its effect on postprandial glycemia compared to 2% milk is unclear. Here, we compared the postprandial glycemic effect of almond milk versus carbohydrate- or caloric-matched 2% milk, each served with oatmeal to patients with type 2 diabetes (T2D). Methods: In this crossover, three-way, open-label study, 22 participants (mean age 66 ± 7.4 years, 36% female), with T2D and overweight or obesity, consumed oatmeal served with almond milk (ALM), carbohydrate-matched 2% milk (MLKCRB), or calorie-matched 2% milk (MLKCAL) on separate days and in a random order. The primary outcome was glucose incremental area under the curve for 240 min (iAUC0-240). The secondary outcomes included postprandial serum insulin, glucagon, plasma free fatty acids (FFAs), serum triglycerides, leptin, and gastrointestinal hormones (PYY, active GLP-1, GIP, amylin, cholecystokinin, and ghrelin). Results: We did not find any difference in either the primary endpoint or secondary endpoints between the three groups. However, iAUC0-240 for insulin and glucagon was significantly higher in MLKCRB vs. ALM (FDR = 0.002 and 0.02, respectively). Conclusions: Almond milk does not offer any additional glycemic benefit over 2% milk and does not differ in its postprandial effects on FFAs, serum triglycerides, leptin, and gastrointestinal hormones over 4 h. Nonetheless, carbohydrate-matched 2% milk elicited greater insulin and glucagon response compared to almond milk, warranting further investigation into its long-term implications.

5 November 2025 in Journal of Diabetes
Verified
Journal Article
Open access
AKAbdelrahman Khater
Abdelrahman Khater
MAMarwa Al-Badri
Marwa Al-Badri
TSTareq Salah
Tareq Salah
SDShilton E. Dhaver
Shilton E. Dhaver
KKKarim Kibaa
Karim Kibaa
OHOsama Hamdy
Osama Hamdy
Introduction: We previously demonstrated that achieving and maintaining ≥ 7% weight loss at 1 year in patients with diabetes (DM), through multidisciplinary intensive lifestyle intervention (ILI) in real‐world clinical practice, predicts improvement in cardiometabolic outcomes at 5 and 10 years. In this prospective follow‐up, we report 15‐year results. Methods: We evaluated 122 patients with DM and obesity (mean age 53.2 ± 10.0 years, 68% females, 90.2% type 2 DM, mean DM duration 9.1 ± 8.6 years, mean BMI 38.4 ± 5.2 kg/m 2 ) who completed a 12‐week ILI program. The cohort achieved an average weight loss of 10.7 ± 4.6 kg (−9.6%, p < 0.001) at 12 weeks and was divided into two groups at 1 year: group A, who maintained < 7% weight loss (47.5%) and group B, who maintained ≥ 7% weight loss (52.5%). Results: At 15 years, the cohort maintained an average weight loss of 8.6 ± 11.9 kg (−7.6%, p < 0.001). Group B demonstrated superior sustained weight loss (12.9 ± 12.0 kg, −11.0%) compared to group A (3.8 ± 10.0 kg, −4.0%) with p < 0.001 between groups. A1C in group B improved from 7.3% ± 1.1% to 6.3% ± 0.8% at 12 weeks and remained at 7.3% ± 1.5% at 15 years, while group A's A1C increased from 6.7% ± 0.9% to 7.9% ± 1.8% ( p = 0.04 between groups). Both groups maintained LDL‐ and HDL‐cholesterol improvements, but group A experienced significant worsening of serum triglycerides. Conclusions: ILI in real‐world clinical practice that results in ≥ 7% weight loss at 1 year in patients with DM and obesity is associated with continued improvement in cardiometabolic outcomes at 15 years.

1 June 2020 in Diabetes
Verified
Journal Article
Closed access
AEAhmed H. Eldib
Ahmed H. Eldib
STShaheen Tomah
Shaheen Tomah
SDShilton E. Dhaver
Shilton E. Dhaver
HGHannah Gardner
Hannah Gardner
MTMhd Wael Tasabehji
Mhd Wael Tasabehji
OHOsama Hamdy
Osama Hamdy
The MiniMed™ 670G (670G) is the first FDA approved hybrid closed-loop insulin delivery system for patients with type 1 diabetes (T1D). In Auto Mode, the integrated continuous glucose monitor (CGM) captures glucose values every five minutes and, via a built-in algorithm, the 670G system automatically adjusts basal insulin delivery targeting a glucose value of 120 mg/dL. Impact of the use of 670G system on patient reported outcomes in people with T1D are limited. Data over one year of use in real world-clinical practice were collected. We evaluated 53 patients with T1D (mean age 46.8±11.8 years, 62% females, body weight 82.5±17.6 kg, BMI 28.7±5.5, HbA1c 7.6±0.8%) who started 670G at the Joslin Clinic between December 2017 and December 2019. Data were collected at baseline and after 12 months. We assessed SROs by administering surveys: 36 Item Short-Form Health Survey (SF 36), Pittsburgh Sleep Quality Index (PSQI), and hypoglycemia fear survey/worry scale (HFS_W). We also measured HbA1c, % time-in-range at baseline and 12 months, and % time in auto mode (TiAM) for the two weeks preceding the final study visit. At 12 months, A1C decreased by 0.3±0.1% from baseline (p<0.01) and % time-in-range increased by 7.9±3.1% from baseline (p=0.015) with no correlation between either of them and %TiAM (p=0.3, p=0.2 respectively). Physical functioning increased by 47.5% from baseline (p<0.001), and HFS_W improved significantly by -16.0% from baseline (p=0.017). At 12 months, average %TiAM was 60.4±33.7% and was not associated with clinical outcomes or SROs. We conclude that use of 670G for a year in real-world clinical practice was associated with significant improvement in A1C, % time-in-range, physical functioning and hypoglycemia fear. Neither of these improvements at 12 months was related to %TiAM. Disclosure A.H. Eldib: None. S. Tomah: Stock/Shareholder; Self; Amarin Corporation. S.E. Dhaver: None. H. Gardner: None. M. Tasabehji: None. M. Albadri: None. A. Atakov-Castillo: None. E. Toschi: None. O. Hamdy: Consultant; Self; Abbott, AstraZeneca, Merck & Co., Inc., Sanofi-Aventis. Research Support; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Healthimation, LLC.